Free Delivery Over $100
|
|
|||
|
||||
Overview1. Discusses enzyme targets that have been used to develop drugs 2. There are many new drugs being developed that particularly target specific enzymes. 3. Biochemists, medicinal chemists, academia and industry 4. Biomolecular science series, MedChemComm 5. The book will survey enzyme targets that have successfully been used to develop clinically-utilized drugs and to describe in detail how these drugs inhibit these particular enzymes. Full Product DetailsAuthor: John F Honek (University of Waterloo) , Zhengding Su (Hubei University of Technology, China) , David E. Thurston , David FoxPublisher: Royal Society of Chemistry Imprint: Royal Society of Chemistry ISBN: 9781849730150ISBN 10: 1849730156 Pages: 250 Publication Date: 05 March 2018 Audience: College/higher education , Professional and scholarly , Postgraduate, Research & Scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Temporarily unavailable  The supplier advises that this item is temporarily unavailable. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out to you. Table of ContentsMechanistic Enzymology and Drug Design; EC Enzyme Class 1: Oxidoreductases; EC Enzyme Class 2: Transferases; EC Enzyme Class 3: Hydrolases; EC Enzyme Class 4: Lyases; EC Enzyme Class 5: Isomerases; EC Enzyme Class 6: Ligases; Where do we go from here?ReviewsAuthor InformationProfessor John F Honek is currently Professor and Chair at the Department of Chemistry, University of Waterloo, Waterloo, Canada. He gained his BSc and PhD in Chemistry at McGill University, Montreal, Canada and was a Postdoctoral Fellow at the Department of Chemistry, MIT, Boston, USA. As a graduate student at McGill, he was involved in the medicinal chemistry of anticancer agents and at MIT, he was involved in mechanistic enzymology. He currently heads a laboratory of 14 students and research associates involved in mechanistic enzymolgy of metalloenzymes and is also involved in the design and synthesis of mechanism-based enzyme inhibitors. He is on the editorial board of 5 journals and has been on Canadian NSERC research grant agency committees. He also has peer reviewed research grants for Canadian, USA and Asian research granting agencies in the areas of biological chemistry and drug design and for several years he was on the Scientific Advisory Board of a California biotechnology company focused on drug design. Tab Content 6Author Website:Countries AvailableAll regions |
||||
